Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

• Main Authors: Le Garff-Tavernier, M, Decocq, J, De Romeuf, C, Parizot, C, Dutertre, C.A, Chapiro, E, Davi, F, Debré, P, Prost, J.F, Teillaud, J.L, Merle-Beral, H, Vieillard, V
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: Nature Publishing Group 2020
• Subjects: antineoplastic agent; CD16 antigen; CD20 antibody; CD56 antigen; Fc receptor IIa; lfb r 603; natural killer cell receptor; rituximab; unclassified drug; Fc receptor; FCGR3B protein, human; glycosylphosphatidylinositol anchored protein; LFB R603; LFB-R603; monoclonal antibody; NCAM1 protein, human; adult; aged; antineoplastic activity; article; autologous hematopoietic stem cell transplantation; B lymphocyte; chronic lymphatic leukemia; cytokine production; cytotoxicity; degranulation; disease course; female; human; in vitro study; low drug dose; major clinical study; male; natural killer cell; priority journal; protein expression; antibody dependent cellular cytotoxicity; immunology; immunophenotyping; middle aged; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD56; Antineoplastic Agents; Female; GPI-Linked Proteins; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, IgG
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/180977
• Institution: National University of Singapore

10.1038/leu.2010.240